Poland· PL-100525935
Brukinsa
A zanubrutinib product containing zanubrutinibum, registered in Poland by BeiGene Ireland Ltd.. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Zanubrutinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EL03 (zanubrutinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Zanubrutinib · ATC L01EL03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of zanubrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.32 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Zanubrutinib · price per daily dose (0.32 g)
USD · FX 28 Sept 2026
- CH Switzerland$188.14
The record
At a glance
URPL (Poland)- Active substance
- Zanubrutinibum
- Manufacturer
- BeiGene Ireland Ltd.
- Country
- Poland (PL)
- ATC code
- L01EL03
- ATC class
- Zanubrutinib
- Defined daily dose
- 0.32 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08720598340389
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
217 interactions on record for zanubrutinib.
Graded by severity as the source publishes them — 140 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zanubrutinib · interactions on record
217 records
- 140 severe
- 77 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zanubrutinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBRUKINSABeOne Medicines USA, Inc.
- SwitzerlandBrukinsa 160 mg, FilmtablettenBeOne Medicines I GmbH
- CzechiaBRUKINSABeOne Medicines Ireland Limited, Dublin
- SpainBRUKINSA 160 MG COMPRIMIDOS RECUBIERTOS CON PELICULABeone Medicines Ireland Limited
- FinlandBRUKINSABeOne Medicines Ireland Limited
- BelgiumBrukinsa 160 mgBeOne Medicines Ireland
- IcelandBrukinsaBeone Medicines Ireland Limited
- NetherlandsBRUKINSA 160 mg filmomhulde tablettenBeiGene Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Brukinsa
- Norway · Brukinsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db80abdb-9a2e-4c49-a4ac-ac2d2dce05ba GET /v1/drugs/db80abdb-9a2e-4c49-a4ac-ac2d2dce05ba?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "160 mg",
"packaging": "08720598340389 ¦ Rpz ¦ EU/1/21/1576/002 ¦ 163968\n60 tabl.",
"substance": "Zanubrutinibum 160 mg",
"common_name": "Zanubrutinibum",
"pl_product_id": "100525935",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about zanubrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.